- Home
- BTAI vs MYNZ Comparison
BTAI vs MYNZ Comparison
Compare BTAI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MYNZ
- Stock Information
- Founded
- BTAI 2017
- MYNZ 2021
- Country
- BTAI United States
- MYNZ Germany
- Employees
- BTAI N/A
- MYNZ N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- MYNZ Health Care
- Exchange
- BTAI Nasdaq
- MYNZ Nasdaq
- Market Cap
- BTAI 8.3M
- MYNZ 7.6M
- IPO Year
- BTAI 2018
- MYNZ 2021
- Fundamental
- Price
- BTAI $1.81
- MYNZ $2.04
- Analyst Decision
- BTAI Buy
- MYNZ Buy
- Analyst Count
- BTAI 5
- MYNZ 2
- Target Price
- BTAI $34.80
- MYNZ $14.00
- AVG Volume (30 Days)
- BTAI 325.6K
- MYNZ 185.7K
- Earning Date
- BTAI 08-05-2025
- MYNZ 08-05-2025
- Dividend Yield
- BTAI N/A
- MYNZ N/A
- EPS Growth
- BTAI N/A
- MYNZ N/A
- EPS
- BTAI N/A
- MYNZ N/A
- Revenue
- BTAI $1,852,000.00
- MYNZ $893,991.00
- Revenue This Year
- BTAI N/A
- MYNZ $26.06
- Revenue Next Year
- BTAI $362.49
- MYNZ $4.97
- P/E Ratio
- BTAI N/A
- MYNZ N/A
- Revenue Growth
- BTAI 5.47
- MYNZ N/A
- 52 Week Low
- BTAI $1.17
- MYNZ $1.34
- 52 Week High
- BTAI $19.84
- MYNZ $19.00
- Technical
- Relative Strength Index (RSI)
- BTAI 48.12
- MYNZ 57.11
- Support Level
- BTAI $1.70
- MYNZ $1.89
- Resistance Level
- BTAI $2.00
- MYNZ $2.25
- Average True Range (ATR)
- BTAI 0.15
- MYNZ 0.22
- MACD
- BTAI -0.03
- MYNZ 0.05
- Stochastic Oscillator
- BTAI 20.00
- MYNZ 76.14
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.